Catalent|13 July 2017

RP Scherer Softgel Technologies

An innovative biotechnology company exploring novel therapeutics for neuroscience indications had developed a promising new chemical entity for the treatment of a severe paediatric genetic disease.

However, numerous drug delivery challenges threatened the realisation of the fast-track status designation they had received due to promising early stage results.

By partnering with Catalent and leveraging our proprietary RP Scherer Softgel technology, the customer was able to overcome a number of potential hurdles and expeditiuosly enter the Phase II/III clinical trial.

Company White Papers

Case Study: Assessing Potential for Oral Delivery Using Parallel Screening

Catalent utilised two technologies targeting duodenal and sublingual biological barriers through a parallel screening approach to assess the oral delivery potential of Salmon Calcitonin.

Case Study: Formulation Prototypes with Increased Solubility and Bioavailability

Catalent Pharma provided London-based pharmaceutical company Trio Medicines with three formulation technologies and four prototypes showing improved solubility and bioavailability for an acetyl prodrug of...

Case Study: Innovative Clinical Supply Solutions

With Catalent's team of packaging experts and extensive cold chain capabilities, this case study discusses the creation of a custom packaging and distribution solution to...

AsiaPacific Region Studies, Common Clinical Supply Challenges

The number of clinical trials in the Asia-Pacific (APAC) region is growing as sponsors tap into expanding pharmaceutical market.

Product enquiry

Your email address *

First name*

Last name*

Company*

Job title*

Country*

Phone*

By downloading, you acknowledge that we may share your information with our partners and sponsors who may contact you directly with information on their products and services. Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for submitting the form. Your enquiry will be submitted to the company.